Table 2.
Baseline phase II patient demographic and clinical characteristics
| Characteristic (n = 26) | Range or percent of total n | |
|---|---|---|
| Median age | 51.0 | Range (25–69) |
| Median number of cycles (1 cycle = 4 weeks) | 2 | Range (1–22) |
| Median follow-up | 10.5 months | Range (0.8–39.6) |
| Her2+ Bbeast cancer | 23 | 88% |
| Prior intrathecal therapy | 2 | 8% |
| Prior WBRT | 13 | 50% |
| Prior SRS | 13 | 50% |
| Concurrent brain mets | 18 | 69% |
| Systemic directed therapy at registration | 10 | 38% |
| New concurrent systemic therapy | 5 | 19% |
| Previously treated for LM | 13 | 50% |